Kentucky HB543 regulates the use of experimental treatments for life-threatening or severely debilitating illnesses.
Kentucky HB543 establishes guidelines for the use of experimental treatments for life-threatening or severely debilitating illnesses. It defines "eligible patients" as those with such conditions who have considered all FDA-approved treatments and received a physician's recommendation for an experimental option. The bill mandates that written, informed consent must include specific details about potential outcomes and risks. It prohibits health insurance policies from being affected by these provisions and shields healthcare providers from disciplinary actions based on their recommendations.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.